Teresa Amaral (T Amaral)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 24

Top Topics

Prognostic Factors

Top Venues

American journal of clinical dermatology

Journal of the European Academy of Dermatology and Venereology : JEADV

Nature medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Felix Peisen, Annika Gerken, Alessa Hering, Isabel Dahm, Konstantin Nikolaou, Sergios Gatidis, Thomas Kurt Eigentler, Teresa Amaral, Jan H Moltz, Ahmed E Othman
Can Delta Radiomics Improve the Prediction of Best Overall Response, Progression-Free Survival, and Overall Survival of Melanoma Patients Treated with Immune Checkpoint Inhibitors? Cancers 16 (15) (2024)
Felix Peisen, Annika Gerken, Alessa Hering, Isabel Dahm, Konstantin Nikolaou, Sergios Gatidis, Thomas Kurt Eigentler, Teresa Amaral, Jan H Moltz, Ahmed E Othman
Can Delta Radiomics Improve the Prediction of Best Overall Response, Progression-Free Survival, and Overall Survival of Melanoma Patients Treated with Immune Checkpoint Inhibitors? Cancers 16 (15) (2024)
T Grünke, S Reiter, S Meyer, J Graf, N Schaeffeler, Ulrike Leiter, Teresa Amaral, Lukas Flatz, A Forschner
Exploring 'decision regret' in adjuvant-treated melanoma patients: Results from a cross-sectional survey on 200 participants. Journal of the European Academy of Dermatology and Venereology : JEADV (2024)
Eftychia Chatziioannou, Ulrike Leiter, Ioannis Thomas, Ulrike Keim, Olivia Seeber, Andreas Meiwes, Isabell Boessenecker, Stephanie Sanchez Gonzalez, Francisco Merraz Torres, Heike Niessner, Tobias Sinnberg, Andrea Forschner, Lukas Flatz, Teresa Amaral
Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy. American journal of clinical dermatology 24 (3) (2023)
Felix Peisen, Annika Gerken, Alessa Hering, Isabel Dahm, Konstantin Nikolaou, Sergios Gatidis, Thomas K Eigentler, Teresa Amaral, Jan H Moltz, Ahmed E Othman
Can Whole-Body Baseline CT Radiomics Add Information to the Prediction of Best Response, Progression-Free Survival, and Overall Survival of Stage IV Melanoma Patients Receiving First-Line Targeted Therapy: A Retrospective Register Study. Diagnostics (Basel, Switzerland) 13 (20) (2023)
Eftychia Chatziioannou, Ulrike Leiter, Ioannis Thomas, Ulrike Keim, Olivia Seeber, Andreas Meiwes, Isabell Boessenecker, Stephanie Sanchez Gonzalez, Francisco Merraz Torres, Heike Niessner, Tobias Sinnberg, Andrea Forschner, Lukas Flatz, Teresa Amaral
Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy. American journal of clinical dermatology 24 (3) (2023)
Claus Garbe, Reinhard Dummer, Teresa Amaral, Rodabe N Amaria, Paolo Antonio Ascierto, Elizabeth M Burton, Brigitte Dreno, Alexander M M Eggermont, Axel Hauschild, Christoph Hoeller, Roland Kaufmann, Celeste Lebbè, Mario Mandala, Alexander M Menzies, David Moreno, Olivier Michielin, Paul Nathan, Sapna Pradyuman Patel, Caroline Robert, Dirk Schadendorf, Paul C Lorigan, Richard A Scolyer, Hussein A Tawbi, Bart A van de Wiel, Christian U Blank, Georgina V Long
Neoadjuvant immunotherapy for melanoma is now ready for clinical practice. Nature medicine (2023)
Eftychia Chatziioannou, Ulrike Leiter, Ioannis Thomas, Ulrike Keim, Olivia Seeber, Andreas Meiwes, Isabell Boessenecker, Stephanie Sanchez Gonzalez, Francisco Merraz Torres, Heike Niessner, Tobias Sinnberg, Andrea Forschner, Lukas Flatz, Teresa Amaral
Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy. American journal of clinical dermatology 24 (3) (2023)
Eftychia Chatziioannou, Ulrike Leiter, Ioannis Thomas, Ulrike Keim, Olivia Seeber, Andreas Meiwes, Isabell Boessenecker, Stephanie Sanchez Gonzalez, Francisco Merraz Torres, Heike Niessner, Tobias Sinnberg, Andrea Forschner, Lukas Flatz, Teresa Amaral
Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy. American journal of clinical dermatology (2023)
Eftychia Chatziioannou, Ulrike Leiter, Ioannis Thomas, Ulrike Keim, Olivia Seeber, Andreas Meiwes, Isabell Boessenecker, Stephanie Sanchez Gonzalez, Francisco Merraz Torres, Heike Niessner, Tobias Sinnberg, Andrea Forschner, Lukas Flatz, Teresa Amaral
Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy. American journal of clinical dermatology 24 (3) (2023)
Eftychia Chatziioannou, Ulrike Leiter, Ioannis Thomas, Ulrike Keim, Olivia Seeber, Andreas Meiwes, Isabell Boessenecker, Stephanie Sanchez Gonzalez, Francisco Merraz Torres, Heike Niessner, Tobias Sinnberg, Andrea Forschner, Lukas Flatz, Teresa Amaral
Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy. American journal of clinical dermatology 24 (3) (2023)
Claus Garbe, Ulrike Keim, Teresa Amaral, Carola Berking, Thomas K Eigentler, Lukas Flatz, Anja Gesierich, Ulrike Leiter, Rudolf Stadler, Cord Sunderkoetter, Thomas Tüting, Jochen Utikal, Uwe Wollina, Lisa Zimmer, Christos C Zouboulis, Paolo Antonio Ascierto, Alexander M M Eggermont, Jean-Jacques Grob, Axel Hauschild, Lidija Kandolf Sekulovic, Georgina V Long, Jason John Luke, Olivier Michielin, Ketty Peris, Dirk Schadendorf, Joanne M Jeter, Paul C Lorigan, null null
Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (32) (2022)
K Schumann, C Mauch, K C Klespe, C Loquai, U Nikfarjam, M Schlaak, L Akcetin, P Kölblinger, M Hoellwerth, M Meissner, G Mengi, A D Braun, M Mengoni, Reinhard Dummer, J Mangana, M A Sindrilaru, D Radmann, C Hafner, J Freund, K Rappersberger, F Weihsengruber, F Meiss, Lydia Reinhardt, F Meier, B Rainer, E Richtig, Julia Maria Ressler, C Höller, T Eigentler, Teresa Amaral, W K Peitsch, U Hillen, W Harth, F Ziller, K Schatton, T Gambichler, L Susok, L V Maul, H Läubli, D Debus, C Weishaupt, S Börger, K Sievers, S Haferkamp, V Zenderowski, V A Nguyen, M Wanner, R Gutzmer, P Terheyden, K Kähler, S Emmert, Alexander Thiem, M Sachse, S Gercken-Riedel, K M Kaune, K M Thoms, L Heinzerling, Markus Vincent Heppt, S Tratzmiller, Wolfram Hoetzenecker, A Öllinger, A Steiner, T Peinhaupt, M Podda, S Schmid, Uwe Wollina, T Biedermann, Christian Posch
Real world outcomes using PD-1 antibodies and BRAF+MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland. Journal of the European Academy of Dermatology and Venereology : JEADV (2022)
Felix Peisen, Annika Hänsch, Alessa Hering, Andreas Stefan Brendlin, Saif Afat, Konstantin Nikolaou, Sergios Gatidis, Thomas Kurt Eigentler, Teresa Amaral, Jan H Moltz, Ahmed E Othman
Combination of Whole-Body Baseline CT Radiomics and Clinical Parameters to Predict Response and Survival in a Stage-IV Melanoma Cohort Undergoing Immunotherapy. Cancers 14 (12) (2022)
Teresa Amaral, Felix Kiecker, Sarah Schaefer, Henner Stege, Katharina Kaehler, Patrick Terheyden, Anja Gesierich, Ralf Gutzmer, Sebastian Haferkamp, Jochen Uttikal, Carola Berking, David Rafei-Shamsabadi, Lydia Reinhardt, Friedegund Meier, Ante Karoglan, Christian Posch, Thilo Gambichler, Claudia Pfoehler, Kai Thoms, Julia Tietze, Dirk Debus, Rudolf Herbst, Steffen Emmert, Carmen Loquai, Jessica C Hassel, Frank Meiss, Thomas Tueting, Vanessa Heinrich, Thomas Eigentler, Claus Garbe, Lisa Zimmer, null null
Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients. Journal for immunotherapy of cancer 8 (1) (2021)
Lina María Serna Higuita, Teresa Amaral, Andrea Forschner, Ulrike Leiter, Lukas Flatz, Olivia Seeber, Ioannis Thomas, Claus Garbe, Thomas Kurt Eigentler, Peter Martus
Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry. Cancers 13 (23) (2021)
Kok Haw Jonathan Lim, Teresa Amaral
Adjuvant and neoadjuvant therapies in melanoma. ESMO open 5 (4) (2021)
Franz J Hilke, Tobias Sinnberg, Axel Gschwind, Heike Niessner, German Demidov, Teresa Amaral, Stephan Ossowski, Irina Bonzheim, Martin Röcken, Olaf Riess, Claus Garbe, Christopher Schroeder, Andrea Forschner
Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients. Cancers 12 (9) (2020)
Teresa Amaral, Martin Schulze, Tobias Sinnberg, Maike Nieser, Peter Martus, Florian Battke, Claus Garbe, Saskia Biskup, Andrea Forschner
Are Pathogenic Germline Variants in Metastatic Melanoma Associated with Resistance to Combined Immunotherapy? Cancers 12 (5) (2020)
Esra Sarac, Teresa Amaral, U Keim, Ulrike Leiter, A Forschner, T K Eigentler, Claus Garbe
Prognostic factors in 161 patients with mucosal melanoma: a study of German Central Malignant Melanoma Registry. Journal of the European Academy of Dermatology and Venereology : JEADV 34 (9) (2020)
Teresa Amaral, Olivia Seeber, Edgar Mersi, Stephanie Sanchez, Ioannis Thomas, Andreas Meiwes, Andrea Forschner, Ulrike Leiter, Thomas Eigentler, Ulrike Keim, Claus Garbe
Primary Resistance to PD-1-Based Immunotherapy-A Study in 319 Patients with Stage IV Melanoma. Cancers 12 (4) (2020)
Teresa Amaral, M Osewold, D Presser, A Meiwes, Claus Garbe, Ulrike Leiter
Advanced cutaneous squamous cell carcinoma: real world data of patient profiles and treatment patterns. Journal of the European Academy of Dermatology and Venereology : JEADV (2019)
Esra Sarac, J Wilhelmi, I Thomas, Ulrike Leiter, U Keim, T K Eigentler, Claus Garbe, Teresa Amaral
Late recurrence of melanoma after 10 years - Is the course of the disease different from early recurrences? Journal of the European Academy of Dermatology and Venereology : JEADV 34 (5) (2019)
Jonas Bochem, Henning Zelba, Teresa Amaral, Janine Spreuer, Daniel Soffel, Thomas Eigentler, Nikolaus Benjamin Wagner, Ugur Uslu, Patrick Terheyden, Friedegund Meier, Claus Garbe, Graham Pawelec, Benjamin Weide, Kilian Wistuba-Hamprecht
Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade. PloS one 14 (8) (2019)